乳腺癌治疗的分子靶点。
Molecular Targets for Breast Cancer Therapy.
机构信息
Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Harry and Diane Rinker Health Science Campus, Irvine, CA 92618, USA.
出版信息
Biomolecules. 2024 Sep 27;14(10):1219. doi: 10.3390/biom14101219.
Abstract
Breast cancer is by far the most common cancer in women, and for a while, it surpassed lung cancer as the most diagnosed cancer, regardless of gender, in 2020 [...].
摘要
乳腺癌是迄今为止女性最常见的癌症，在 2020 年，它有一段时间超过肺癌，成为无论性别最常见的诊断癌症[...]。
相似文献
1
Molecular Targets for Breast Cancer Therapy.乳腺癌治疗的分子靶点。
Biomolecules. 2024 Sep 27;14(10):1219. doi: 10.3390/biom14101219.
2
[Locally advanced breast cancer (methods of treatment)].[局部晚期乳腺癌（治疗方法）]
Vopr Onkol. 2011;57(5):553-8.
3
[Strategies of breast cancer treatment based on determination of biological subtype].基于生物学亚型判定的乳腺癌治疗策略
Vopr Onkol. 2011;57(5):542-52.
4
Targeted therapies in the treatment of breast cancer and localized sarcomas.乳腺癌和局限性肉瘤治疗中的靶向疗法。
Curr Med Chem. 2013;20(5):593-5. doi: 10.2174/092986713804999394.
5
Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?人表皮生长因子受体2阳性乳腺癌的靶向治疗：活性药物会过多吗？
J Clin Oncol. 2011 Aug 10;29(23):3111-3. doi: 10.1200/JCO.2011.36.4091. Epub 2011 Jul 5.
6
Progress in breast cancer: overview.乳腺癌的进展：概述。
Clin Cancer Res. 2013 Dec 1;19(23):6353-9. doi: 10.1158/1078-0432.CCR-13-2549.
7
Breast cancer in 2012: New drugs, new knowledge, new targets.2012年的乳腺癌：新药、新知识、新靶点。
Nat Rev Clin Oncol. 2013 Feb;10(2):75-6. doi: 10.1038/nrclinonc.2012.236. Epub 2013 Jan 8.
8
Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began.乳腺癌靶向治疗的演进：精准医学的起源
Am Soc Clin Oncol Educ Book. 2018 May 23;38:78-86. doi: 10.1200/EDBK_201037.
9
[Endocrinology of breast cancer as a heterogeneous disease: a decade after the millennium].[作为异质性疾病的乳腺癌内分泌学：千年之后的十年]
Vopr Onkol. 2013;59(3):292-8.
10
Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.曲妥珠单抗-恩杂鲁胺用于晚期HER2阳性乳腺癌及其他情况：基于基因组图谱的靶点
Expert Rev Anticancer Ther. 2013 Jan;13(1):5-8. doi: 10.1586/era.12.152.
引用本文的文献
1
The Expression and Clinical Significance of ALDOA in Breast Cancer.醛缩酶A（ALDOA）在乳腺癌中的表达及临床意义
Onco Targets Ther. 2025 Aug 4;18:845-862. doi: 10.2147/OTT.S518473. eCollection 2025.
2
Targeting Resistance Pathways in Breast Cancer Through Precision Oncology: Nanotechnology and Immune Modulation Approaches.通过精准肿瘤学靶向乳腺癌的耐药途径：纳米技术与免疫调节方法
Biomedicines. 2025 Jul 10;13(7):1691. doi: 10.3390/biomedicines13071691.
3
The potential mechanism of Saikosaponin D against luminal A breast cancer based on bioinformatical analysis, molecular docking and in vitro studies.基于生物信息学分析、分子对接和体外研究探讨柴胡皂苷D抗腔面A型乳腺癌的潜在机制
Hereditas. 2025 Jul 24;162(1):140. doi: 10.1186/s41065-025-00510-8.
4
Analysis of Serum Soluble Endoglin and s-CD105 Levels in Relation to Postoperative Recurrence and Metastasis in Breast Cancer Patients Treated with Modified Radical Mastectomy.改良根治术治疗的乳腺癌患者血清可溶性内皮糖蛋白和可溶性CD105水平与术后复发及转移的关系分析
Int J Womens Health. 2025 May 31;17:1597-1604. doi: 10.2147/IJWH.S515952. eCollection 2025.
5
Anticancer Potential of Prebiotics: Targeting Estrogen Receptors and PI3K/AKT/mTOR in Breast Cancer.益生元的抗癌潜力：针对乳腺癌中的雌激素受体和PI3K/AKT/mTOR
Biomedicines. 2025 Apr 18;13(4):990. doi: 10.3390/biomedicines13040990.
6
Lactate Dehydrogenase-A-Forming LDH5 Promotes Breast Cancer Progression.生成乳酸脱氢酶A的LDH5促进乳腺癌进展。
Breast Cancer (Dove Med Press). 2025 Feb 12;17:157-170. doi: 10.2147/BCTT.S502670. eCollection 2025.
本文引用的文献
1
A self-targeting MOFs nanoplatform for treating metastatic triple-negative breast cancer through tumor microenvironment remodeling and chemotherapy potentiation.一种自靶向 MOFs 纳米平台，通过肿瘤微环境重塑和化疗增效治疗转移性三阴性乳腺癌。
Int J Pharm. 2024 Oct 25;664:124625. doi: 10.1016/j.ijpharm.2024.124625. Epub 2024 Aug 30.
2
Targeting apoptotic pathways for cancer therapy.针对癌症治疗的凋亡途径。
J Clin Invest. 2024 Jul 15;134(14):e179570. doi: 10.1172/JCI179570.
3
Glutathione-responsive CD-MOFs co-loading honokiol and indocyanine green biomimetic active targeting to enhance photochemotherapy for breast cancer.谷胱甘肽响应型 CD-MOFs 共载霍宁醇和吲哚菁绿仿生主动靶向增强乳腺癌光化疗。
Int J Pharm. 2024 Jul 20;660:124310. doi: 10.1016/j.ijpharm.2024.124310. Epub 2024 Jun 6.
4
FDA approves first-in-class AKT inhibitor.美国食品药品监督管理局批准首款一流的AKT抑制剂。
Nat Rev Drug Discov. 2024 Jan;23(1):9. doi: 10.1038/d41573-023-00202-w.
5
Designing Nanomedicines for Breast Cancer Therapy.设计用于乳腺癌治疗的纳米药物。
Biomolecules. 2023 Oct 22;13(10):1559. doi: 10.3390/biom13101559.
6
The Expression of Trace Amine-Associated Receptors (TAARs) in Breast Cancer Is Coincident with the Expression of Neuroactive Ligand-Receptor Systems and Depends on Tumor Intrinsic Subtype.痕量胺相关受体（TAARs）在乳腺癌中的表达与神经活性配体-受体系统的表达一致，并取决于肿瘤内在亚型。
Biomolecules. 2023 Sep 7;13(9):1361. doi: 10.3390/biom13091361.
7
Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories.靶向乳腺癌：已知领域、新兴领域与未知领域
Biomolecules. 2023 Aug 25;13(9):1306. doi: 10.3390/biom13091306.
8
Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer.开发三阴性乳腺癌靶向疗法的挑战与机遇。
Biomolecules. 2023 Aug 1;13(8):1207. doi: 10.3390/biom13081207.
9
Adenosine/β-Cyclodextrin-Based Metal-Organic Frameworks as a Potential Material for Cancer Therapy.基于腺嘌呤/β-环糊精的金属有机骨架作为癌症治疗的潜在材料。
Biomolecules. 2023 Jul 20;13(7):1154. doi: 10.3390/biom13071154.
10
Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia.靶向细胞周期和凋亡以克服急性髓系白血病的化疗耐药性。
Leukemia. 2023 Jan;37(1):143-153. doi: 10.1038/s41375-022-01755-2. Epub 2022 Nov 18.
Zotero 插件